What is it about?
•Malignant peritoneal cytology was associated with 32% increased risk of recurrence in stage I-III endometrial cancer. •Malignant peritoneal cytology was associated with 37% increased risk of all-cause mortality in stage I-III endometrial cancer. •These hazard estimates are attenuated with adjuvant therapy. •There was interaction between peritoneal cytology status and adjuvant therapy effect on survival.
Featured Image
Photo by Europeana on Unsplash
Read the Original
This page is a summary of: Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol, Gynecologic Oncology, October 2025, Elsevier,
DOI: 10.1016/j.ygyno.2025.08.029.
You can read the full text:
Contributors
The following have contributed to this page
